title: Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
abstract: Gliomas are the most common and primary tumors of the central nervous system in adults. Temozolomide (TMZ) is the main drug used to treat glioma; however, prognosis remains poor for most patients. Glioma stem cells (GSCs) are thought to enable glioma initiation and evasion from immune surveillance; their immunogenicity can be determined by expression of major histocompatibility complex (MHC)-I. The present study investigated the effect of TMZ on MHC-I expression in GSCs. Glioma spheres were cultured in serum-free medium containing epidermal growth factor, basic fibroblast growth factor, and B27; MHC-I expression was detected by immunocytochemistry, quantitative real-time PCR, and flow cytometry. Nuclear factor (NF)-κB expression in glioma stem cells was detected by Western blot. TMZ enhanced MHC-I expression in GSCs, and NF-κB was activated. TMZ treatment increased MHC-I expression via modulation of NF-κB signaling in GSCs. In addition to being a chemotherapeutic agent, TMZ may also serve as an immunomodulatory agent in the treatment of glioma patients.
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang 110001, China.
authors.forename: Dongyong
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang 110001, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Qiu
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang 110001, China.
authors.forename: Yunjie
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang 110001, China.
authors.forename: Yanlei
authors.initials: Y
authors.lastname: Guan
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang 110001, China.
authors.forename: Luyang
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang 110001, China.
authors.forename: Anhua
authors.initials: A
authors.lastname: Wu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004357:Drug Synergism; D005805:Genes, MHC Class I / Q000187:drug effects*; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000378:metabolism; D061251:Primary Cell Culture / Q000379:methods; D015398:Signal Transduction / Q000187:drug effects; D013234:Stem Cells / Q000187:drug effects; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D016328:NF-kappa B; D003606:Dacarbazine; D000077204:Temozolomide
keywords: MHC-I; T cells; flow cytometry; immunology; stem cells